News
Sumitomo Pharma America, Inc. (SMPA) presented new, positive data from the COURAGE Phase 3 open-label extension study of vibegron (GEMTESA®) in men living with overactive bladder (OAB) and receiving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback